The buccal micronucleus cytome (BMNcyt) assay in uncultured exfoliated epithelial cells from oral mucosa is widely applied in biomonitoring human exposures to genotoxic agents and is also proposed as a suitable test for prescreening and follow-up of precancerous oral lesions. The main limitation of the assay is the large variability observed in the baseline values of micronuclei (MNi) and other nuclear anomalies mainly related to different scoring criteria. The aim of this international collaborative study, involving laboratories with different level of experience, was to evaluate the inter-and intra-laboratory variations in the BMNcyt parameters, using recently implemented guidelines, in scoring cells from the same pooled samples obtained from healthy subjects (control group) and from cancer patients undergoing radiotherapy (treated group). The results indicate that all laboratories correctly discriminated samples from the two groups by a significant increase of micronucleus (MN) and nuclear bud (NBUD) frequencies and differentiated binucleated (BN) cells, associated with the exposure to ionizing radiation. The experience of the laboratories was shown to play an important role in the identification of the different cell types and nuclear anomalies. MN frequency in differentiated mononucleated (MONO) and BN cells showed the greatest consistency among the laboratories and low variability was also detected in the frequencies of MONO and BN cells. A larger variability was observed in classifying the different cell types, indicating the subjectivity in the interpretation of some of the scoring criteria while reproducibility of the results between scoring sessions was very good. An inter-laboratory calibration exercise is strongly recommended before starting studies with BMNcyt assay involving multiple research centers.
Introduction
The buccal micronucleus cytome (BMNcyt) assay in uncultured exfoliated epithelial cells from oral mucosa is a minimally invasive approach for evaluating genomic damage, chromosomal instability and cell death in human aerodigestive tract (1) (2) (3) (4) (5) . The assay was widely applied in biomonitoring studies to evaluate occupational or environmental exposures to genotoxins (1, 3) , medical procedures (5-7), micronutrient deficiencies (8, 9) , lifestyle factors (10) (11) (12) and genetic susceptibility (13) (14) (15) (16) . Moreover, increased micronucleus (MN) frequencies in exfoliated buccal cells are associated with the risk of developing cancer and degenerative diseases (17) . Furthermore, the test seems to be a promising approach for prescreening and follow-up of precancerous oral lesions (17) .
The large majority of MN studies in buccal cells are focused on the evaluation of the MN frequency (1) (2) (3) . Micronuclei (MNi) are a biomarker for structural and/or numerical chromosome aberrations because MNi are a consequence of the formation of acentric chromosome fragments or lagging whole chromosomes, not properly segregated during mitotic anaphase and excluded from the main daughter nuclei (18) . However, cell death biomarkers such as pyknosis, karyolysis and karyorrhexis were also evaluated in some studies, because their inclusion in assessment provides a more comprehensive evaluation of cytotoxicity and could increase the sensitivity and scope of biomonitoring studies (19) (20) (21) (22) (23) . It is for this reason that the buccal MN assay involves the novel cytome approach now adopted almost universally amongst MN tests including the most widely used method, the lymphocyte cytokinesis-block MN cytome assay (18) .
The main limitation in the practical application of the MN cytome assays in clinics as well as for monitoring occupational and environmental exposures is the variability among the studies. Host factors, such as inter-individual variability in metabolism, DNA repair capacity, cell proliferation, multiple exposures to exogenous and endogenous agents alter the cell differentiation and could interfere with MN expression and susceptibility to cell death. Moreover, methodological differences in collection of cells, fixation, staining procedures, number of cells counted and scoring criteria has been shown to affect the results (1, 24, 25) .
In 2007, the international HUMN (Human Micronucleus) project (www.humn.org) coordinating group started a validation project of the MN assay in exfoliated buccal cells (HUMN XL project 'XL' designating eXfoLiated cell) (26, 27) . A detailed standardised protocol for buccal cell collection, slide preparation and scoring was established by taking into account the available procedures, confounding factors and staining artifacts (28, 29 ).
An analysis of data obtained in 58 worldwide laboratories that reported the use of the assay in international peer-reviewed journals was carried out. The most important and statistically significant source of variability for the MN frequency, was shown to be the method used for staining buccal cells with further effects depending on the cell collection method and scoring criteria used (30) . A comprehensive set of photomicrographs with multiple examples of each cell type and nuclear anomalies associated with detailed scoring criteria was also recently published by the HUMNxl project, as a basis for a slide scoring exercise to assess the inter-laboratory variability (31) .
A first exercise, carried out among three experienced laboratories scoring the same set of slides, showed a good agreement among the laboratories in regard to the main parameters associated with the evaluation of chromosomal damage (MNi in mononucleated and binucleated differentiated cells), while some inconsistencies were observed in the identification of cell types and/or nuclear anomalies, such as the frequencies of basal cells (BASAL), binucleated (BN) cells, condensed chromatin (CC) and karyorrhectic cells (KHC) (32) . On the basis of these results guidelines for slide scoring were improved by better defining the nucleus: cytoplasm area ratio to characterise basal, transitional and differentiated cells, by combining CC and KHC cells anomalies associated with cell death into a single CC/KHC category and by more carefully classifying the different types of nuclear buds (NBUDs) to avoid misclassification as BN cells.
Subsequently, as a follow-up of this initiative, an international exercise was organised, which included laboratories with different level of experience to evaluate the scoring reproducibility within and among laboratories. The variability attributable to sample storage and processing was not addressed in this study.
The aims of this expanded collaborative study were: a) to evaluate the inter-laboratory variations in the buccal cytome assay scores when a common set of improved criteria are used in scoring cells from the same pooled samples b) to determine the extent of variation in the scores obtained by different scorers from the same lab using the same set of criteria and identical slides c) to determine the extent of variation in the results obtained by the same scorer using the same set of criteria and the same slides This article describes the outcomes of this inter-laboratory scoring exercise conducted by 13 laboratories from ten countries.
Materials and methods
A preparatory 1-week training course for laboratories who expressed their interest in participating in this exercise was organised in parallel in Genoa, Environmental Carcinogenesis Unit, IRCCS AOU San Martino IST-Istituto Nazionale per la Ricerca sul Cancro, and in Vienna Institute of Cancer Research-Medical University in September-October 2014. The program of the training course was coordinated between the organizing laboratories and involved the application of the standardised BMNcyt protocol and scoring criteria. The course was available to laboratories with different level of experience, from those with many years and substantial number of publications on the BMcyt to the laboratories that only recently started to apply the assay. Its purpose was to present the improved guidelines for slide scoring developed on the basis of the results of the first inter-calibration exercise among the references laboratories. The course involved sample preparation, staining and scoring of the different cellular types and nuclear alterations.
Subject recruitment
The study was approved by the local Ethical Advisory Board at the IRCCS AOU San Martino-IST, in Genoa. The study involved a total of 13 participants including healthy controls and head and neck cancer patients undergoing radiotherapy. Nine head and neck cancer patients (5 males and 4 females aged 56-77 years, including 4 smokers, 2 ex-smokers and 3 nonsmokers) and 4 age-matched healthy controls (3 females and 1 male age 30-60 years, all nonsmokers) were recruited at the Environmental Carcinogenesis Unit, IRCCS AOU San Martino-IST, Genoa, Italy. The range of the cumulative radiation dose received by the head and neck cancer patients in oral region of the head was between 20 and 22 Gy.
Buccal cell collection, slide preparation and staining
Buccal cells were collected from both cheeks using a small-headed tooth brush following the standardised protocol (28) . Samples were transferred from the toothbrush into Saccomanno's fixative (Histoline laboratories, Milano, Italy) and stored at 4°C for 1-2 months until processing.
Samples were processed at the Environmental Carcinogenesis Unit, IRCCS AOU San Martino-IST-Genoa, Italy following the previously reported standardised protocol (28) . Briefly, exfoliated buccal cells were transferred into centrifugation tubes and spun for 10 min at 580 g at room temperature. The supernatants were removed and replaced with 10 ml of buccal cell buffer [0.01M TrisHCl (Sigma T-3253), 0.1M EDTA tetra sodium salt (Sigma E-5391) 0.02 M sodium chloride (Sigma S5886) at pH 7.0]. Cells were resuspended and spun at 580 g for 10 min, then washed twice in the same buffer. The suspensions were briefly vortexed and then homogenised for 2-3 min in a hand homogeniser (Wheaton Scientific 0.1-0.15 mm gauge) at medium intensity, to increase the number of single cells in the suspensions. Samples from subjects belonging to each group (cancer patients and healthy controls) were pooled in a 50-ml tube and drawn into a syringe with a 21G gauge needle (Becton Dickinson and Company Limited, Drogeda, Ireland), then expelled to improve cellular separation. Subsequently, the cells were passed through a 100-μm nylon filter (Millipore, code NYH02500) held in a swinnex holder (Millipore, code SX0002500) to remove large cell aggregates. Cells were further spun at 580 g for 10 min and the supernatant removed. They were re-suspended in 10 ml of buccal cell buffer and the cell concentration determined using a counting chamber (Burker hemocytometer). Cell suspensions were prepared containing 80 000 cells/ml of buccal cell buffer. About 50 µl of dimethyl sulphoxide (Sigma D1435) per milliliter of cell suspension were added to further improve cell separation. About 120 µl of each cell suspension were added to each cytospin cup and spun at 40.65 g (600 rpm) for 5 min in a cytocentrifuge (Shandon Cytospin 3, Thermo Electron Corporation). Slides containing one spot of cells were air dried for 10 min and then fixed in ethanol:acetic acid (3:1) for 10 min. Subsequently, slides were air dried for at least 10 min.
Fixed slides were treated for 1 min each in 50% ethanol, and then 20% ethanol and subsequently washed with deionised water for 2 min prior to staining. The slides were then treated with 5.0 M hydrochloric acid for 30 min at room temperature followed by washing for 3 min in running tap water. Moist slides were treated with Schiff's reagent (Sigma 3552016) at room temperature in the dark for 60 min, washed in running tap water for 5 min and rinsed in deionised water. Slides were stained in 0.2% Light Green (Histoline Laboratories, Polyscience Inc code 02753) for 30 s, rinsed in deionised water and allowed to air dry at room temperature prior to being mounted in DPX mounting medium (a mixture of Distyrene, a Plasticiser and Xylene) (Sigma 44581).
Twenty-five slides were prepared from each pooled sample from the two different groups of subjects, treated cancer patients and controls.
Scoring process
Three laboratories who were involved in the development of the revised BMNcyt scoring methodology (28, 31) and in the first interlaboratory scoring comparison (32) participated in this exercise as reference laboratories: (i) the Environmental Carcinogenesis Unit, IRCCS AOU San Martino-IST-Genova, Italy; (ii) the Institute of Cancer Research, Medical University of Vienna. Austria and (iii) CSIRO Food and Nutrition, Adelaide, Australia. These reference laboratories are referred to as Ref1, Ref2 and Ref3.
The laboratories participating in the International inter-laboratory scoring exercise are listed in Table 1 . Each participating laboratory was provided with: (i) a standard set of scoring criteria (28, 31) ; and (ii) two stained slides, one from controls and second one from treated patients pooled cells. Slides were coded so the scorers were not aware of the identity of the group they belong to.
All laboratories provided information on the level of experience of the scorers with the BMNcyt assay and with the HUMNxl scoring criteria. Some of the laboratories with more than 1 scorer had a different level of experience among the participants, ranging from many years in the field to recently trained scorers.
The scorers were classified for each evaluated biomarker as 'experienced' if they had already learnt and applied the HUMNxl scoring criteria in previous studies and they were classified as 'less experienced' if they were only starting to learn and use the criteria.
Coded slides were scored using transmitted light at ×1000 magnification. Mononucleated (MONO) and BN cells containing MNi or NBUDs on bright field were confirmed as being positive by also examining the cells under far red fluorescence as previously described (28, 31) . The scorer(s) from each laboratory evaluated the slides twice. A stepwise approach was applied to score the slides (Figure 1) . First, the frequencies of various cell types identified following the detailed criteria as described previously (28, 31) were evaluated in 1000 cells. In a second step of analysis, 2000 differentiated mononuclear (DIFF_ MONO) cells were scored for nuclear abnormalities indicative of chromosomal instability or DNA damage. In a third step, nuclear anomalies (MNi and NBUDs) were scored in 100 binucleated differentiated (DIFF_BN) cells.
Statistical methods
Descriptive analysis was performed by computing means and standard deviations of the biomarkers from each laboratory, session and scorer. For each biomarker, the ratio between the means of treated and controls [i.e. mean ratio (MR)] (17), stratified by laboratory, and its 95% confidence interval were computed. The MRs were reported in forest plots using the logarithmic scale. To assess the consistency of the scoring adjusting by the treatment effect, the MRs between the means from participating laboratories and the means of pooled data from the three reference laboratories (Ref1, Ref2 and Ref3 see Table 1 ) were computed. This analysis was performed applying the Poisson regression model to the scoring results. We verified the suitability of the Poisson model with a goodness of fit test (33) . In presence of extra-Poisson variability, i.e. overdispersion, the negative binomial regression model was applied for fitting data (33) . By means of this model, the medium percent change (MPC), i.e. (MR − 1)*100 for each laboratory respect to any biomarker was computed.
Finally, we applied to the scoring results the multilevel mixedeffects Poisson regression models (34) . This model is applied when data exhibit a hierarchical structure with respect to the strata of some variables, i.e. the laboratory and the scorer in this case. The model allows to estimate as fixed effects the MRs linked to the predictors included in the model, and as random effects the heterogeneity between laboratories and between scorers within laboratories in predicting the scoring results. The predictors included in the model were the treatment (i.e. whether the result was from the healthy controls or the cancer patients treated with radiotherapy), and the laboratory experience, encoded by a binary variable (yes/no), i.e. if the scorers had already learnt and applied the HUMNxl scoring criteria (31) in previous studies, as described above. In this model, Ref1, Ref2 and Ref3 contribute to the total variability as individual laboratories. The aim of this exercise was to estimate the residual variability between laboratories and scorers after adjusting for the experience which is the most noticeable variable among the laboratories. P < 0.05 were considered to be statistically significant. All analyses were performed using Stata 13 Software (35). Figure 2 shows distribution of BMNcyt biomarker values expressed as MR in pooled buccal cells from cancer patients in comparison to healthy controls. The purpose of this analysis was to verify which biomarker better discriminated the two sample groups and the extent of its consistency between laboratories. It is clear that frequency of MNC_MONO and NBUDC_MONO together with DIFF_BN distinguish the two groups well since either all or almost all the confidence intervals do not include the zero value which, in logarithmic scale, indicates no difference between irradiated cells and controls. KHC appears to be a less sensitive biomarker in discriminating the two groups. These results are consistent among the laboratories although the effect estimates vary. Figure 3 shows the laboratories that significantly differ in biomarkers scoring compared to the combined data of the three reference laboratories. MPC (i.e. (MR − 1)*100 as estimated from regression models adjusting by treatment) in significant increase/decrease are plotted for each biomarker. MNC_MONO and MNI_MONO showed the greatest consistency among the laboratories, followed by MNC_BN and MNI_ BN and DIFF_MONO values. Few statistically significant differences in MNC_MONO or MNI_MONO frequencies were observed in participating laboratories in comparison with the reference laboratories with one laboratory recording lower counts and two having higher counts. MNC_BN values (MPC range −56%/−44%) and MNI_BN (MPC range −63%/−41%) show significant decreases among laboratories.
Results
DIFF_MONO results from the participating laboratories had only small variations relative to the reference laboratories with MPC ranging between −18% and +16%; in DIFF_BN the variation was slightly larger compared to DIFF_MONO (MPC range −44%/+54%). The rates for BASAL frequencies deviated significantly from those of the reference laboratories in a few of the participating laboratories (MPC range −80%/+433%) but the gaps are broad.
MPCs for CC cell frequency ranged from −89% and +273%. KHC cell frequency differed between the reference and many participating laboratories, (MPC range −66%/+213%). Combining the CC+KHC values (MPC range −71%/+177%) resulted in a reduction of the heterogeneity among the laboratories for these cell death markers. Karyolytic (KYL) cells (MPC range −51%/+108%) revealed an acceptable agreement between all laboratories. Even larger differences were seen for PYK cells relative to the reference laboratories (MPC range −96%/+665%). A number of participating laboratories differed from the reference laboratories for the values of all NBUDs to a great extent: NBUDC_MONO (MPC range +93%/+814%), NBUDC_BN (MPC range +329%/+401%), NBUDS_MONO (MPC range +102%/+811%), NBUDS_BN (MPC range +427%/+433%), that indicates that these biomarkers are not consistently evaluated using the current criteria, and may be less reliable.
In Tables 3 and 4 are shown the results from the multilevel mixedeffects Poisson regression models. In this model, Ref1 Ref2 and Ref3 contribute to the total variability as individual laboratories. Table 3 reports the effect of the scoring session (repeated analysis by the same scorer at a different time) after adjustment for (i) treatment (i.e. treated patients or controls), and (ii) heterogeneity between laboratories. The MRs are almost all close to one, with the exception of BASAL and PYK, and no MR is statistically significant indicating a good agreement between two scoring sessions.
A statistically significant effect of treatment was observed for all biomarkers except PYK after adjusting for experience and the heterogeneity between laboratories and between scorers within laboratories ( Table 4 ). All markers were higher in the cancer patients with the exceptions of DIFF_MONO, CC, KHC, CC+KHC. MN frequencies in DIFF_ MONO and in DIFF_BN cells seem to be the most suitable markers to detect the genotoxic effects of irradiation exposure in buccal cells.
Considering the 'experience' factor, we observed statistically significant effects for DIFF_MONO, BASAL, CC, CC+KHC and PYK and, with exception of DIFF_MONO, less experience in scoring the slides leads to an overestimation in the counting of these parameters.
After removing the effects of 'treatment' and 'experience', the heterogeneity of scoring between laboratories remains statistically significant for DIFF_MONO, BASAL, CC and KHC while the variability of the scorers within laboratories remains below the significance threshold. The MN frequency in MONO and BN cells appears as the most robust biomarker of the BMNcyt assay for which there is the best agreement between laboratories.
Discussion
The practical application of the BMNcyt assay in clinics as well in monitoring occupational exposures requires the identification of the factors responsible for the large variability in the baseline values of MNi and other nuclear anomalies observed in published studies (26, 30) .
This study focused on the analysis of the variability attributable to the scoring process which is the critical step in the BMNcyt assay.
A previous scoring exercise produced evidence for good agreement among the three experienced reference laboratories on the main parameters associated with the evaluation of chromosomal damage, such as MNi in DIFF_MONO and DIFF_BN (32) .
The aim of this international collaborative study involving laboratories with different level of experience was to evaluate the interand intra-laboratory variation in the BMNcyt assay results using a common set of criteria by scoring cells from two pooled samples from treated cancer patients and controls with different frequencies of cell types and nuclear abnormalities.
The key result of this exercise is that all participating laboratories correctly discriminated the irradiated samples from the control cells, as shown by a statistically significant increase in the MN and NBUD frequencies and in the number of DIFF_BN cells. However, the scores of the other cell types included in the BMNcyt assay approach Ref1 (8) Ref2 (4) Ref3 (8) Ref1+Ref2+ Ref3 (20) Lab1 (4) Lab2 (4) Lab3 (12) Lab4 (8) Lab5 (7) Lab6 (4) Lab7 (4) Lab8 (4) Lab9 (8) Lab10 ( The number of score values for each laboratory included the repeated scoring of two slides (from cancer patients and controls) by the scorer(s). such as BASAL, BN, CC and KHC cells did not show a consistent effect related to the radiation exposure, and therefore were deemed less reliable using current set of criteria.
The main target of ionizing radiation is the DNA molecule. Double-strand breaks (DSBs) and non-DSB highly clustered DNA lesions, consisting of a combination of single-strand breaks (SSBs), abasic sites and oxidised bases, expressed as chromosomal aberrations are the main effects induced by the exposure to ionizing radiations (36, 37) . The dicentric metaphase assay and the cytokinesis-block MN test in peripheral lymphocytes are the best validated methods for biodosimetry and diagnostic dose indicators recommended by the International Atomic Energy Agency (38) . The frequency of cell types measuring the differentiation process and cell death, included in the BMNcyt assay approach, are mainly associated with cytotoxic effects or normal morphogenesis in buccal mucosa and only partly linked with radiation damage.
The inter-laboratory variation among participating laboratories was evaluated through the comparison with the data from the reference laboratories. The parameters showing the greatest consistency among the laboratories are MN frequencies in DIFF_MONO and DIFF_BN cells. Furthermore, the numbers for the frequencies of DIFF_MONO and DIFF_BN cells had low variability increasing the consistency for the identification of MNi and other nuclear abnormalities in these target cells. Large inter-laboratory variability was observed in values of different cell types such as CC, KHC, KYL and PYK cells, with greatest variability seen for the latter type. A reduction of variability was obtained after combining CC and KHC cells, confirming the recommendation from our previous scoring exercise amongst reference laboratories to combine these two biomarkers into a single score (32) .
The possible determinants of the inter-laboratory variability could be identified in a subjective interpretation of the scoring criteria based on the previous experience with the BMNcyt assay and possibly on the quality of the microscopes used in the exercise. The experience of the laboratories was shown to play an important role in the identification of the different cell types and nuclear anomalies. This effect was more relevant in the scoring of BASAL, CC and PYK cells with an overestimation in less experienced laboratories.
A good reproducibility of the scoring between sessions was observed for all the parameters included in the BMNcyt assay. No significant difference, after adjustment for the treatment and the inter-laboratory heterogeneity, was detected between the two scoring sessions for any participating laboratories. This result indicates a robustness of the criteria for the majority of parameters of the BMNcyt assay. The difficulty in visually assessing the size of cells and nuclei probably best explains the misclassification of some cell types mainly identified by the nuclear/cytoplasm area ratio such as BASAL and PYK cells.
The main conclusion of this study is that the current visual scoring criteria are sufficiently robust to obtain consistent results concerning the identification of differentiated cells and MNi which represent the main biomarkers for the evaluation of chromosomal damage in buccal exfoliated cells. It is important to emphasise the need for proper training by experienced laboratory scientists. The inter-calibration among the laboratories is strongly recommended to allow proper and reliable comparisons of the parameters included in BMNcyt assay approach across laboratories in studies with multiple participating centers. Further studies are needed to identify the relevant host factors responsible for the inter-and intra-individual variability in the MN frequency in order to minimise their impact on the results of biomonitoring studies. Next steps in the validation of the MN test in buccal exfoliated cells will involve the analysis of the baseline frequency in healthy subjects for the cell types associated with cell differentiation and cell death included in the BMNcyt assay approach and the identification of biological confounding factors (e.g. genetics, nutrition, genotoxic exposures) relevant for explaining its variability in order to define the role of these parameters in human biomonitoring studies.
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